DGAP-News: Jens Henneke joins Delenex Therapeutics AG as Business and Corporate Development Advisor
(firmenpresse) - EQS Group-News: Delenex Therapeutics AG / Key word(s): Change of
Personnel
Jens Henneke joins Delenex Therapeutics AG as Business and Corporate
Development Advisor
12.11.2013 / 17:39
---------------------------------------------------------------------
Jens Hennecke joins Delenex Therapeutics AG as Business and Corporate
Development Advisor
Schlieren/Zurich, 12 November 2013. Delenex Therapeutics AG, a
biotechnology company developing topical and local treatments for
dermatologic diseases using its proprietary PENTRA(R)Bodies, today
announced that it has engaged Jens Hennecke, PhD, as Business and Corporate
Development Advisor.
Dr. Jens Hennecke (46) has a strong track record in business development,
corporate development and licensing. He brings extensive experience in the
negotiation and closing of corporate alliances. Prior to joining Delenex
and building his own business development advisory franchise, he held the
position of Senior Vice President Business Development at Micromet, Inc.
where he played a key role in establishing partnerships with major pharma
companies, as well as in Micromet's acquisition by Amgen in 2012. Dr.
Hennecke holds a B.Sc. in biology from the University of Göttingen,
Germany, and a Ph.D. from the ETH Zurich, Switzerland.
Dr. Thomas Hecht, Executive Chairman of Delenex mentioned, 'We are pleased
and proud to have attracted Jens with his international experience and
strong business development and licensing background. We are convinced
that Jens will add to the success of Delenex and spearhead our business
development activities to add new partnerships.'
'I am very much looking forward to working with Delenex,' said Dr. Jens
Hennecke. 'Delenex has a strong pipeline of PENTRA(R)Bodies and advanced
clinical projects, including topical treatments of dermatologic diseases.
This provides for significant partnering opportunities beyond Novartis'
exclusive use of the platform for ophthalmic diseases.'
About Delenex Therapeutics AG
Delenex is a privately-held biopharmaceutical company focused on the
development of locally or topically applied antibody therapeutics. Thereby
Delenex aims at extending the benefits of proven antibody therapeutics to a
much larger number of patients. Delenex' proprietary PENTRA(R) platform
will deliver such novel, potent and safe antibody therapeutics that are
well suited for local/topical application.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a
Novartis company).
For further details, please contact:
Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Zürich-Schlieren
E-mail: jakob.schlapbach(at)delenex.com
Website: www.delenex.com
End of Corporate News
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=JGSHMFVMBY
Document title: Jens Henneke joins Delenex Therapeutics AG
---------------------------------------------------------------------
12.11.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
239426 12.11.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.11.2013 - 17:39 Uhr
Sprache: Deutsch
News-ID 315517
Anzahl Zeichen: 6001
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Jens Henneke joins Delenex Therapeutics AG as Business and Corporate Development Advisor"
steht unter der journalistisch-redaktionellen Verantwortung von
Delenex Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
